Is Compounded Tirzepatide Still Available in 2026?

*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting, stopping, or changing any medication. Compounded medications are not FDA-approved.*

*Last updated: June 1, 2026. This page is updated as the regulatory situation evolves.*

---

If you are researching whether you can still get compounded tirzepatide in 2026, the short answer is: yes, but under conditions that are meaningfully different from two years ago.

The regulatory landscape shifted in October 2024 when the FDA removed tirzepatide from its drug shortage list. Courts upheld that decision. Enforcement discretion periods expired. And in 2026, the FDA sent warning letters to telehealth companies making misleading claims about compounded GLP-1 medications.

Through all of that, a legal pathway remains. Licensed 503A compounding pharmacies can still prepare tirzepatide for individual patients when a licensed prescriber documents a specific clinical reason why the commercially available product does not meet that patient's needs.

This article explains what changed, what stayed the same, and what questions to ask before starting or continuing compounded tirzepatide.

---

A Quick Overview: What Is Compounded Tirzepatide?

Tirzepatide is the active ingredient in Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management), both manufactured by Eli Lilly.

In the SURMOUNT-1 trial, adults with obesity who took tirzepatide 15mg once weekly lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% in the placebo group (Jastreboff et al., NEJM, 2022, PMID: 35658024). Results in people with type 2 diabetes were similarly significant: the SURMOUNT-2 trial found an average 14.7% weight reduction at 72 weeks compared to 3.2% on placebo (Garvey et al., Lancet, 2023, PMID: 37385275).

Compounded tirzepatide is a version of tirzepatide prepared by a licensed compounding pharmacy based on an individual patient's prescription. It is not FDA-approved as a finished product and has not undergone the same manufacturing review as Mounjaro or Zepbound. The clinical trial results above are for the brand-name formulations and should not be assumed to apply to compounded versions.

The appeal for many patients has been cost. Brand-name tirzepatide can run $900 to $1,400 per month without insurance. Compounded versions have historically been available at a substantially lower price point.

---

How Compounded Tirzepatide Became Available in the First Place

To understand the current situation, it helps to understand the legal framework that made widespread compounded tirzepatide possible.

Under the Federal Food, Drug, and Cosmetic Act, licensed pharmacies are generally not allowed to compound medications that are essentially copies of commercially available drugs. There is, however, a significant exception.

When a drug appears on the FDA's official drug shortage list, licensed compounding pharmacies can legally prepare that medication, even if it is essentially a copy of a commercially available product. This exception exists specifically to protect patient access when commercial supply fails.

Tirzepatide appeared on the FDA shortage list in mid-2023 as demand for Mounjaro and Zepbound outpaced Eli Lilly's manufacturing capacity. Under the shortage exemption, hundreds of licensed 503A pharmacies began compounding tirzepatide for individual patients, and telehealth platforms connected those patients with prescribers and pharmacy services at scale.

---

October 2024: The FDA Removes Tirzepatide from the Shortage List

On October 2, 2024, the FDA determined that tirzepatide products were no longer in shortage and removed them from the shortage list. Unlike semaglutide, whose shortage removal sparked a prolonged legal battle, the tirzepatide removal moved relatively quickly through the courts.

The compounding industry challenged the FDA's decision, arguing that supply remained insufficient for certain patient populations and dosage strengths. On May 7, 2025, a federal district court in the Northern District of Texas upheld the FDA's determination. The court found the agency's shortage resolution to be legally sound.

With the shortage designation removed and legal challenges exhausted, the broad shortage-based exemption for tirzepatide compounding expired.

---

What This Means for 503A Pharmacies Today

The shortage exemption's end did not make all compounded tirzepatide illegal. It changed which legal pathway applies.

503A pharmacies are state-licensed compounding pharmacies that prepare medications based on patient-specific prescriptions from licensed providers. After the shortage exemption expired, 503A pharmacies can still legally prepare compounded tirzepatide, but with a critical requirement: the prescription must reflect a documented individual medical need that the commercially available product cannot meet.

In practice, this means the prescribing provider must identify a specific clinical reason why Mounjaro or Zepbound is not appropriate for that particular patient. Examples of legitimate documented needs include:

• A documented allergy or hypersensitivity to an inactive ingredient in the brand-name formulation
• A requirement for a dosage strength not commercially available (for example, during a customized titration protocol)
• A documented clinical reason requiring a different delivery mechanism or formulation

Cost preference or general insurance coverage gaps alone do not constitute medical necessity under the current FDA framework. The compounded product also cannot be substantively identical to the commercially available product without that individualized medical justification.

503B outsourcing facilities, which compound medications at larger scale for healthcare facilities without patient-specific prescriptions, face a more restricted landscape. FDA enforcement discretion periods for 503B compounders who were operating under the shortage exemption have expired. 503B facilities seeking to continue compounding tirzepatide must meet separate legal requirements, and the FDA proposed in April 2026 to permanently exclude tirzepatide from the bulk drug substances list that 503B facilities rely on for certain non-shortage compounding.

---

The 2026 Enforcement Wave: What FDA Warning Letters Mean for Patients

In February 2026, the FDA sent warning letters to approximately 30 telehealth companies. The primary concern: these companies were making claims that compounded GLP-1 medications were equivalent to, or the same as, FDA-approved brand-name products.

For patients, the warning letters do not directly change access to compounded tirzepatide through compliant providers. They signal that the FDA is actively monitoring the market and taking action against providers who make misleading claims.

What to watch for when evaluating a provider:

• Providers stating their compounded tirzepatide is "the same as Zepbound" or "FDA-approved" are making a false claim.
• Providers who describe it as "generic tirzepatide" are using inaccurate terminology.
• Compliant providers describe their medication accurately: it contains tirzepatide as the active ingredient, it is compounded by a licensed 503A pharmacy, and it is not FDA-approved.

---

---

Is Compounded Tirzepatide Safe?

The safety profile of tirzepatide as an active ingredient is well-documented from large clinical trials. A 2026 review published in Expert Opinion on Drug Safety examined the accumulated tirzepatide safety data and confirmed a known but manageable adverse effect profile, with gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation) being the most common concerns, particularly during dose escalation (Janić M, Expert Opinion on Drug Safety, 2026, PMID: 42201797).

A comparative review in Frontiers in Medicine (2026) found tirzepatide's cardiovascular and glycemic outcomes comparable to or better than semaglutide in available clinical trial data (Harbi MH, Frontiers in Medicine, 2026, PMID: 42100257).

A real-world cohort study published in the Journal of Mid-Life Health (2026) found that tirzepatide produced clinically meaningful weight loss in overweight and obese midlife adults both with and without type 2 diabetes, consistent with the trial data (Agrawal PK, Journal of Mid-Life Health, 2026, PMID: 42124821).

The safety data above is from studies of FDA-approved tirzepatide (Mounjaro and Zepbound). Compounded tirzepatide has not been separately studied in equivalent safety or efficacy trials. That said, the active ingredient is the same. The meaningful quality variables are: the source and purity of the API (active pharmaceutical ingredient), pharmacy compounding practices, sterility, and proper storage and handling.

What this means practically: Compounded tirzepatide prepared by a licensed 503A pharmacy using pharmaceutical-grade API from an FDA-registered source, following USP sterile compounding standards, and shipped under appropriate cold chain conditions, contains the same active ingredient as the brand-name product. Because the finished compounded product has not been studied in its own clinical trials, quality and consistency depend on the pharmacy's practices rather than on FDA approval of the finished product.

---

How to Evaluate a Provider in 2026

The 2026 regulatory environment has created a clearer divide between compliant providers and those operating outside the rules. Here is what to look for:

Pharmacy partner transparency: A legitimate provider should be able to tell you the name of the compounding pharmacy filling your prescription, confirm it is a licensed 503A facility (state-licensed and regulated), and confirm it uses pharmaceutical-grade API.

Medical necessity documentation: A compliant prescriber will take a clinical history and document the specific medical justification for a compounded formulation in your record. If an online intake form takes two minutes and asks no real clinical questions, that is worth scrutinizing.

Accurate language: Your provider's materials should accurately describe compounded tirzepatide as a compounded medication, not FDA-approved, containing tirzepatide as the active ingredient. They should not claim it is equivalent to Mounjaro or Zepbound.

Ongoing medical oversight: Regular check-ins with a licensed provider, not just automated refill approvals, support both safety and compliance.

Reasonable pricing: If pricing seems unusually low or the process seems designed to move as many patients through as quickly as possible without individualized care, that is worth pausing on.

---

Frequently Asked Questions

Is compounded tirzepatide legal in 2026?

Yes, through licensed 503A pharmacies when a licensed prescriber documents specific individual medical necessity. Broad compounding based solely on the former shortage exemption is no longer a valid legal basis.

Can I still get compounded tirzepatide if I do not have insurance coverage for Zepbound?

Lack of insurance coverage is not itself considered medical necessity under the current FDA framework for 503A compounding. However, if your provider can document a clinical reason you need a compounded formulation (for example, a specific dosage strength not commercially available, or a documented allergy), you may still qualify. Discuss your specific situation with a licensed provider.

How is compounded tirzepatide different from Zepbound?

Both contain tirzepatide as the active ingredient. Zepbound has undergone full FDA manufacturing review and approval. Compounded tirzepatide has not. Inactive ingredients and formulations may differ. Quality depends on the compounding pharmacy's practices.

What happened to the shortage exemption?

The FDA removed tirzepatide from its shortage list in October 2024. A court upheld that decision in May 2025. The shortage-based exemption that allowed broad compounding no longer applies.

Will compounded tirzepatide still be available later in 2026?

The current 503A pathway remains legally intact. The FDA's April 2026 proposal to exclude tirzepatide from the 503B bulks list primarily affects larger outsourcing facilities, not individual-patient 503A compounding. The public comment period on that proposal closes in June 2026. The 503A landscape is not directly affected by the 503B rule, though the overall regulatory direction reflects increased FDA scrutiny of GLP-1 compounding.

Is Prescriva a licensed pharmacy?

Prescriva is a telehealth management services organization. Your prescription would be filled by a state-licensed 503A compounding pharmacy that Prescriva partners with. Prescriva works only with pharmacy partners operating in compliance with current federal and state requirements.

---

The Bottom Line

Compounded tirzepatide remains available through licensed 503A compounding pharmacies in 2026 for patients with documented individual medical needs. The rules governing that access are stricter than they were during the shortage period, and the FDA is actively enforcing against providers who misrepresent compounded medications.

If you are currently using compounded tirzepatide and it is working well for you, the most important step is to ensure your provider has a documented clinical rationale in your record and that your prescription is filled by a licensed, compliant 503A pharmacy.

If you are considering starting tirzepatide for the first time, speak with a licensed healthcare provider who can review your medical history, confirm whether a compounded formulation is appropriate for your situation, and connect you with a pharmacy partner that meets current compliance standards.

*This article is for informational purposes only and does not constitute medical or legal advice. Always consult a licensed healthcare provider for guidance specific to your situation.*

---

*Sources:*

1. *Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024.*
2. *Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PMID: 37385275.*
3. *Janić M. Tirzepatide data: safety always comes first! Expert Opin Drug Saf. 2026 May 27. PMID: 42201797.*
4. *Harbi MH et al. Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials. Front Med. 2026. PMID: 42100257.*
5. *Agrawal PK et al. Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study. J Mid-life Health. 2026;17(1). PMID: 42124821.*